مورد إلكتروني
Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study
| العنوان: | Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study |
|---|---|
| المصدر: | Lung Cancer |
| بيانات النشر: | Elsevier Ireland Ltd. 2012 |
| تفاصيل مُضافة: | Gately, Kathy Al-Alao, Bassel Dhillon, Tony Mauri, Francesco Cuffe, Sinead Seckl, Michael O'Byrne, Kenneth |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background: A recent study by Dhillon et al. [12], identified both angioinvasion and mTOR as prognostic biomarkers for poor survival in early stage NSCLC. The aim of this study was to verify the above study by examining the angioinvasion and mTOR expression profile in a cohort of early stage NSCLC patients and correlate the results to patient clinico-pathological data and survival. Methods: Angioinvasion was routinely recorded by the pathologist at the initial assessment of the tumor following resection. mTOR was evaluated in 141 early stage (IA-IIB) NSCLC patients (67 - squamous; 60 - adenocarcinoma; 14 - others) using immunohistochemistry (IHC) analysis with an immunohistochemical score (IHS) calculated (% positive cells × staining intensity). Intensity was scored as follows: 0 (negative); 1+ (weak); 2+ (moderate); 3+ (strong). The range of scores was 0-300. Based on the previous study a cut-off score of 30 was used to define positive versus negative patients. The impact of angioinvasion and mTOR expression on prognosis was then evaluated. Results: 101 of the 141 tumors studied expressed mTOR. There was no difference in mTOR expression between squamous cell carcinoma and adenocarcinoma. Angioinvasion (p= 0.024) and mTOR staining (p= 0.048) were significant univariate predictors of poor survival. Both remained significant after multivariate analysis (p= 0.037 and p= 0.020, respectively). Conclusions: Our findings verify angioinvasion and mTOR expression as new biomarkers for poor outcome in patients with early stage NSCLC. mTOR expressing patients may benefit from novel therapies targeting the mTOR survival pathway. © 2011 Elsevier Ireland Ltd. |
| مصطلحات الفهرس: | 80 and over, Aged, Angioinvasion, Blood Vessels, Carcinoma, Early stage NSCLC, Humans, Immunohistochemistry (IHC), Lung Neoplasms, MTOR inhibitors, Mammalian target of rapamycin (mTOR), Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Non-Small-Cell Lung, Poor prognostic factor, TOR Serine-Threonine Kinases, adult, aged, article, biochemical marker, cancer invasion, cancer staging, clinical feature, correlation analysis, drug targeting, everolimus, female, histopathology, human, human tissue, immunohistochemistry, lung adenocarcinoma, lung non small cell cancer, lung squamous cell carcinoma, major clinical study, male, mammalian target of rapamycin, mammalian target of rapamycin inhibitor, prediction, priority journal, prognosis, protein expression, ridaforolimus, scoring system, survival rate, temsirolimus, tissue microarray, Contribution to Journal |
| URL: | doi:10.1016/j.lungcan.2011.06.012 Gately, Kathy, Al-Alao, Bassel, Dhillon, Tony, Mauri, Francesco, Cuffe, Sinead, Seckl, Michael, & O'Byrne, Kenneth (2012) Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study. Lung Cancer, 75(2), pp. 217-222. |
| الإتاحة: | Open access content. Open access content Consult author(s) regarding copyright matters This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au |
| أرقام أخرى: | ATUTQ oai:eprints.qut.edu.au:65054 Faculty of Health; Institute of Health and Biomedical Innovation; School of Biomedical Sciences 864712054 |
| المصدر المساهم: | QUEENSLAND UNIV OF TECH From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.ocn864712054 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |